UCB's Bimzelx approved in Japan for plaque psoriasis

24 January 2022
ucb_large

Belgium biopharma UCB (Euronext: UCB) today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for Bimzelx (bimekizumab) for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma in patients who are not sufficiently responding to existing treatments.

Bimekizumab is the first approved psoriasis treatment in Japan that is designed to selectively and directly inhibit two key cytokines driving inflammatory processes – interleukin 17F (IL-17F) and interleukin 17A (IL-17A). UCB’s shares were down 2.5% at 88.84 euros by late morning trading.

This announcement marks the third approval for bimekizumab worldwide, following marketing authorization in countries of the European Union/European Economic Area and Great Britain in August 2021 for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology